Skip to main content
Equibles
RCUS logo

RCUS · Arcus Biosciences, Inc. · Metrics

Track RCUS — free

Use RCUS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RCUS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$18.14 +0.38 (+2.14%) At close · Oct 27 Q2 2026 earnings call transcript
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$2.26B
Shares
127.33M
Volume · Oct 27 2.23M Avg daily vol (3M) 1.76M

RCUS metrics

77 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$18.14
Market cap
$2.26B

Price action

20 metrics
Price change (1W)
-23.6%
Price change (30D)
-27.5%
Price change (3M)
-32.9%
Price change (6M)
-26.9%
Price change (YTD)
-23.9%
Price change (1Y)
-2.5%
Trailing year
Price change (5Y)
-45.2%
52-week high
$31.57
52-week low
$17.76
Change from 52-week high
-42.5%
Change from 52-week low
+2.1%
Annualized volatility
62.0%
Annualized volatility (3M)
60.7%
Beta
1.5
RSI (14D)
28.2
Price vs SMA 50
-29.3%
Price vs SMA 200
-26.7%
Avg volume (3M)
1.76M
Relative volume
1.3
Average dollar volume
$43.62M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
127.33M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
18.9×
reciprocal yield 5.3%
EV / EBITDA
—
EV / EBIT
—
P / sales
19.3×
reciprocal yield 5.2%
P / book
4.9
reciprocal yield 20.5%
FCF yield
-21.0%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-20.3%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
14.8×
reciprocal yield 6.7%
EV / revenue historical average (5Y)
14.8×
reciprocal yield 6.7%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-05

Profitability

9 metrics
Gross margin
—
Operating margin
-415.4%
Trailing 12 months
Net margin
-393.2%
Gross profit (TTM)
—
Operating profit (TTM)
−$486.00M
Net income (TTM)
−$460.00M
Trailing 12 months
Diluted EPS (TTM)
$-3.89
FCF margin
-406.0%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$5.04

Growth

11 metrics
Revenue growth YoY
-74.4%
Year over year
Net income growth YoY
—
Revenue (TTM)
$117.00M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+18.4%
Year over year · more shares
Revenue CAGR (3Y)
+30.2%
Revenue CAGR (5Y)
+25.9%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-99.1%
Return on assets
-49.8%
Debt / equity
0.2
Current ratio
3.8
EBITDA (TTM)
−$476.00M
Free cash flow (TTM)
−$475.00M
Quick ratio
3.8
Interest coverage
-44.2
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$49.00M
Latest balance sheet
Cash & equivalents
$150.00M
Total assets
$924.00M
Total debt
$101.00M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$474.00M
Capital expenditures (TTM)
$1.00M
R&D (TTM)
$497.00M
SG&A (TTM)
—
Stock compensation (TTM)
$63.00M
R&D / revenue
424.8%
Stock compensation / revenue
53.8%

Ownership (13F)

9 metrics
13F filers
233
13F filer change QoQ
+21
Institutional ownership
96.7%
Conviction holders (share of 13F filers)
2.6%
Crowding (high-turnover and private-fund holders)
20.6%
Private-fund adviser ownership
19.4%
Active holders' share change QoQ
+1.7%
Holder tenure
11.2
Price vs estimated holder cost
+65.4%

Ownership (registered funds)

1 metrics
Index-fund ownership
21.0%

Short interest

3 metrics
Short interest
9.7%
Latest settlement · 9.7 days to cover
Days to cover
9.7d
Short-squeeze score
59 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$84,810
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1724521 CUSIP 03969F109 13F (30d) 37 filings 37 filers Visit website Investor relations